Message from the CEO - Allinky Biopharma

The increasing market complexity for the pharmaceutical industry is pushing them to focus on many other aspects of business apart from innovation. More and more every day small but highly flexible, fast and academic-connected biotechnology companies are taking the lead for discovering innovative therapeutics. Allinky as a biotech takes advantage of this market trend by becoming a valuable partner for the pharmaceutical industry as well as an active stakeholder with a social commitment to bring quality of life to patients.

As a representative of the company founders who mainly come from the scientific and clinical arena, please allow me to share with you that Allinky has a personal commitment - a sort of DNA imprinting attitude to discover new treatments for the disabling diseases and cancer. Within our founders’ lab we have discovered that many chronic diseases respond to a common pattern of chronic stimulation of inflammatory signals within our body’s cells. These chronic diseases may range from Alzheimer’s disease to osteoarthritis and may also include metabolic diseases such as type II diabetes and  cardiovascular diseases such as atherosclerosis. Moreover, our founders have also identified cell signals behind the uncontrolled progression of certain tumor cells and even their turning into metastatic cancer cells.

To render cell missignalling in all these diseases we have embarked in a intensive journey to discover novel therapeutics that change the shape of protein targets and thus modulating their activation status. If we hopefully touch ground at the end of the journey, these novel therapeutics will represent a step forward in the treatment of cancer, inflammation and chronic inflammatory conditions. We are working hard every day to fulfill the expectations we raised on our pharmaceutical partners and moreover on those suffering life-threatening or untreatable diseases.

Thank you for visiting our website!